Car-T-Cell therapy for cancer treatment

Abstract

Chimeric Antigen Receptor (CAR)-T cells are one of the most promising innovations in cancer treatment. CAR-T cells are particularly suitable for treating hematologic cancers, including leukemias and lymphomas. Experimental T-cells are modified genetically and show antennas definite to cancer cells. It may, therefore, detect cancer cells more easily and destroy them. In a patient, the T-cells are extracted, carriers of CAR are injected in vitro, and the altered cells are reinfused through the blood. The procedure has expressed outstanding outcomes in certain leukemias and lymphomas, with recuperative rates in patients who have completed all available conventional therapies. Despite this, some difficulties remain, like cytokine explosion syndrome, neurotoxicity, and low efficacy in solid tumors. This review aims to provide a brief overview of the current status of CAR-T cell therapy and discuss prospective future implications of the treatment in cancer.